Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T, Hauber V, Pahl J, Klapproth K, Wu W, Dobrota I, Herweck F, Reichling J, Helm L, Schroeder T, Li B, Weidner P, Zhan T, Eckardt M, Betge J, Belle S, Sticht C, Gaiser T, Boutros M, Ebert MPA, Cerwenka A, Burgermeister E. Gutting T, et al. Among authors: betge j. Oncoimmunology. 2021 May 5;10(1):1906500. doi: 10.1080/2162402X.2021.1906500. Oncoimmunology. 2021. PMID: 34026331 Free PMC article.
MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
Zhan T, Ambrosi G, Wandmacher AM, Rauscher B, Betge J, Rindtorff N, Häussler RS, Hinsenkamp I, Bamberg L, Hessling B, Müller-Decker K, Erdmann G, Burgermeister E, Ebert MP, Boutros M. Zhan T, et al. Among authors: betge j. Nat Commun. 2019 May 16;10(1):2197. doi: 10.1038/s41467-019-09898-0. Nat Commun. 2019. PMID: 31097693 Free PMC article.
The drug-induced phenotypic landscape of colorectal cancer organoids.
Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, Herweck F, Srour-Mhanna K, Miersch T, Valentini E, Boonekamp KE, Hauber V, Gutting T, Frank L, Belle S, Gaiser T, Buchholz I, Jesenofsky R, Härtel N, Zhan T, Fischer B, Breitkopf-Heinlein K, Burgermeister E, Ebert MP, Boutros M. Betge J, et al. Nat Commun. 2022 Jun 6;13(1):3135. doi: 10.1038/s41467-022-30722-9. Nat Commun. 2022. PMID: 35668108 Free PMC article.
A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM, Betge J, Gutting T, Burgermeister E, Belle S, Zhan T, Schulte N, Maenz M, Ebert MP, Haertel N. Meindl-Beinker NM, et al. Among authors: betge j. BMC Cancer. 2019 Mar 14;19(1):231. doi: 10.1186/s12885-019-5446-2. BMC Cancer. 2019. PMID: 30871493 Free PMC article. Clinical Trial.
Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
Bamberg LV, Heigwer F, Wandmacher AM, Singh A, Betge J, Rindtorff N, Werner J, Josten J, Skabkina OV, Hinsenkamp I, Erdmann G, Röcken C, Ebert MP, Burgermeister E, Zhan T, Boutros M. Bamberg LV, et al. Among authors: betge j. Int J Cancer. 2022 Nov 1;151(9):1586-1601. doi: 10.1002/ijc.34155. Epub 2022 Jun 28. Int J Cancer. 2022. PMID: 35666536 Free article.
Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA. Burgermeister E, et al. Among authors: betge j. Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156678 Free PMC article.
CRISPR/Cas9 for cancer research and therapy.
Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. Zhan T, et al. Among authors: betge j. Semin Cancer Biol. 2019 Apr;55:106-119. doi: 10.1016/j.semcancer.2018.04.001. Epub 2018 Apr 16. Semin Cancer Biol. 2019. PMID: 29673923 Free article. Review.
45 results